Dr. Sujit Sheth, MD
Claim this profileWeil Cornell Medicine
Studies Thalassemia
Studies Beta Thalassemia
2 reported clinical trials
2 drugs studied
Affiliated Hospitals
Clinical Trials Sujit Sheth, MD is currently running
Luspatercept
for Thalassemia
This trial is testing a drug called luspatercept in children with β-thalassemia to see if it is safe and how it works in their bodies. The study includes children who need regular blood transfusions and those who do not. Luspatercept helps the body make more red blood cells, which can lessen the need for transfusions. Luspatercept is a newly approved treatment for reducing the need for blood transfusions in adults.
Recruiting1 award Phase 210 criteria
Benserazide
for Beta Thalassemia
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.The diseases are characterized by hemolytic anemia, organ damage, and early mortality without treatment. Increases in another type of (normal) hemoglobin, fetal globin (HbF), which is normally silenced in infancy, reduces anemia and morbidity. Even incremental augmentation of fetal globin is established to reduce red blood cell pathology, anemia, certain complications, and to improve survival. This trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice. The study drug acts by suppressing 4 repressors of the fetal globin gene promoter in progenitor cells from patients. The drug has been used for 50 years in a combination product for different actions - to enhance half-life and reduce side effects of a different active drug- and is considered safe for long-term use. This trial will first evaluate 3 dose levels in small cohorts of nontransfused patients with beta thalassemia intermedia. The most active dose will then be evaluated in larger subject groups with beta thalassemia and other hemoglobinopathies, such as sickle cell disease.
Recruiting1 award Phase 1 & 25 criteria
More about Sujit Sheth, MD
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sujit Sheth, MD has experience with
- Benserazide Only Product
- Luspatercept
Breakdown of trials Sujit Sheth, MD has run
Beta Thalassemia
Sickle Cell Anemia
Sickle Cell Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sujit Sheth, MD specialize in?
Sujit Sheth, MD focuses on Thalassemia and Beta Thalassemia. In particular, much of their work with Thalassemia has involved beta thalassemia mutation positive patients, or patients who are undergoing treatment.
Is Sujit Sheth, MD currently recruiting for clinical trials?
Yes, Sujit Sheth, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Sujit Sheth, MD has studied deeply?
Yes, Sujit Sheth, MD has studied treatments such as Benserazide Only Product, Luspatercept.
What is the best way to schedule an appointment with Sujit Sheth, MD?
Apply for one of the trials that Sujit Sheth, MD is conducting.
What is the office address of Sujit Sheth, MD?
The office of Sujit Sheth, MD is located at: Weil Cornell Medicine, New York, New York 10065 United States. This is the address for their practice at the Weil Cornell Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.